Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Sub-study for Systemic Lupus Erythematosus (SLE)
Active SLE as defined by the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) classification
Diagnosed with SLE more than 24 weeks before screening visit
Sub-study for primary Sjögren's Syndrome (pSS)
Moderate to severe pSS, meeting ACR-EULAR classification criteria
Sub-study for active Rheumatoid Arthritis (RA)
Moderate to severe adult-onset RA
ACR global functional status class I to III
Women and men must agree to follow instructions for methods of contraception.
You may not be if
Sub-study for SLE
Certain other autoimmune diseases and overlap syndromes
Sub-study for pSS
Certain other immune-mediated diseases, active fibromyalgia, or other medical conditions
Sub-study for RA
Diagnosis with juvenile arthritis or idiopathic arthritis before age 16
For all sub-studies:
History of any significant drug allergy
Active infection, significant concurrent medical condition, or clinically significant abnormalities
Clareo Health | Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
